Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allogene Therapeutics Inc.

1.91
+0.00500.26%
Volume:1.41M
Turnover:2.67M
Market Cap:399.43M
PE:-1.24
High:1.95
Open:1.91
Low:1.85
Close:1.90
Loading ...

Allogene to invest $37.3M in expanded MRD assay pact with Foresight Diagnostics

TIPRANKS
·
26 Feb

Allogene Therapeutics Inc - Expanded Collaboration to Develop Mrd Assay in EU, UK, Canada, Australia

THOMSON REUTERS
·
26 Feb

Allogene Therapeutics Inc - on Feb 19. Amended Strategic Collaboration Agreement With Foresight Diagnostics

THOMSON REUTERS
·
26 Feb

Allogene Therapeutics Inc: Expands Strategic Partnership With Foresight Diagnostics

THOMSON REUTERS
·
26 Feb

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

GlobeNewswire
·
26 Feb

Baird ‘encouraged’ by Allogene CAR-T therapy update

TIPRANKS
·
19 Feb

Allogene Therapeutics Up Nearly 42%, on Pace for Record Percent Increase -- Data Talk

Dow Jones
·
15 Feb

William Blair Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)

TIPRANKS
·
14 Feb

BRIEF-Allogene Therapeutics Announces Publication Of Durable Response Data From Phase 1 Alpha/Alpha2 Trials Of The Allogeneic Car T Cemacabtagene Ansegedleucel/Allo-501

Reuters
·
14 Feb

Allogene publishes data from ALPHA, ALPHA2 trials of cemacabtagene ansegedleucel

TIPRANKS
·
14 Feb

Allogene Therapeutics Announces Publication of Durable Response Data From Phase 1 Alpha/Alpha2 Trials of the Allogeneic Car T Cemacabtagene Ansegedleucel/Allo-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

THOMSON REUTERS
·
14 Feb

Allogene Therapeutics Inc - Cema-Cel Achieves Orr of 58% and Cr of 42% in Study

THOMSON REUTERS
·
14 Feb

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

GlobeNewswire
·
14 Feb

Allogene Therapeutics Announces Participation in February Investor Conferences

GlobeNewswire
·
04 Feb

FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases

Zacks
·
30 Jan

Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer

THOMSON REUTERS
·
29 Jan